ArticleOncotarget2015
A functional variant in miR-155 regulation region contributes to lung cancer risk and survival.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The relationship of miR-155 host gene polymorphism in the susceptibility of cancer: a systematic review and meta-analysis.Frontiers in genetics · 2025Pooled it
- The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis.BMC cancer · 2019Pooled it
- Genetic Polymorphisms of miR-146a and miR-155 in Psoriasis and Psoriatic Arthritis: Evidence from a Turkish Case-Control Study.Dermatology practical & conceptual · 2026Article
- Association of Epistatic Effects of lncRNA GAS5, miR-146a, IRAK-1, and miR-155 Genetic Variants with Multiple Sclerosis Risk and Severity.Molecular neurobiology · 2025Article
- Clinical Relevance ofInternational journal of molecular sciences · 2025Article
- Article
- Pharmacogenetic Analysis of theGenes · 2023Article
- Inflammatory microRNAs in cardiovascular pathology: another brick in the wall.Frontiers in immunology · 2023Review
- Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Article
- Dysregulation of Plasma miR-146a and miR-155 Expression Profile in Mycosis Fungoides Is Associated with rs2910164 and rs767649 Polymorphisms.International journal of molecular sciences · 2022Article
- Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation.International immunopharmacology · 2022Review
- miR-155-3p: processing by-product or rising star in immunity and cancer?Open biology · 2022Review
- Dysregulated transient receptor potential channel 1 expression and its correlation with clinical features and survival profile in surgical non-small-cell lung cancer patients.Journal of clinical laboratory analysis · 2022Article
- Dysregulation of circulating CDC42 and its correlation with demographic characteristics, comorbidities, tumor features, chemotherapeutic regimen and survival profile in non-small-cell lung cancer patients.Journal of clinical laboratory analysis · 2022Article
- MiR-146a and miR-155 polymorphisms in Egyptian patients with Behcet's disease.Archives of medical science : AMS · 2022Article
- Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.International journal of molecular sciences · 2021Review
- MicroRNAs as New Regulators of Neutrophil Extracellular Trap Formation.International journal of molecular sciences · 2021Review
- Role of microRNAs in Lung Carcinogenesis Induced by Asbestos.Journal of personalized medicine · 2021Review
- The Impact of Air Pollution Exposure on the MicroRNA Machinery and Lung Cancer Development.Journal of personalized medicine · 2021Review
- Evaluation Expression of miR-146a and miR-155 in Non-Small-Cell Lung Cancer Patients.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence suggested that upregulation of miR-155 could serve as a promising marker for the diagnosis and prognosis of non-small cell lung cancer (NSCLC). In the present study, we genotyped rs767649 (A > T) located in miR-155 regulation region in 1341 cases and 1982 controls, and analyzed the associations of rs767649 with NSCLC risk and survival. Consequently, rs767649 exhibited the significant associations with the risk (adjusted OR = 1.12, 95% CI = 1.01-1.24, P = 0.031) and prognosis of NSCLC (adjusted HR = 1.17, 95% CI = 1.03-1.32, P = 0.014). Meanwhile, rs767649 specifically interacted with radio-chemotherapy (P(int) = 0.013), and patients with both the rs767649-TT genotype and radio-chemotherapy had the highest hazard ratio (adjusted HR = 1.65, 95% CI = 1.26-2.16, P < 0.001). Furthermore, using functional assays and The Cancer Genome Atlas (TCGA) Lung Adenocarcinoma (LUAD) dataset, we found that rs767649 variant allele could increase the transcriptional activity of miR-155, which in turn facilitated tumor growth and metastasis by inhibiting HBP1, TJP1, SMAD5 and PRKAR1A expression. Our findings suggested that rs767649 A > T might contribute to the increased risk and poor prognosis of NSCLC, highlighting the importance of rs767649 in the prevention and therapy of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.